a b c d e Moriguchi et al., Supplementary Fig. S1

Slides:

Advertisements

Similar presentations

Fig. 4-1, p Fig. 4-2, p. 109 Fig. 4-3, p. 110.

Advertisements

Slide 1Fig. 15.1, p.453. Slide 2Fig. 15.1a, p.453.

Judith Croasmun. HGA1C: What is it??  The A1C is the average of the blood sugar over a 2-3 month time period.  The A1C measures the amount of sugar.

Slide 1Fig. 11.1, p.337. Slide 2Fig. 11.2, p.338.

Slide 1Fig. 19.1, p Slide 2Fig. 19.2, p. 583.

Slide 1Fig. 21.1, p.641. Slide 2Fig. 21.2, p.642.

Slide 1Fig. 10.1, p.293. Slide 2Fig. 10.1a, p.293.

Slide 1Fig. 5.1, p.113. Slide 2Fig. 5.1a, p.113 Slide 3Fig. 5.1b, p.113.

Fig. 11-1, p p. 360 Fig. 11-2, p. 361 Fig. 11-3, p. 361.

Fig. 3-1, p. 67. Fig. 3-2, p. 67 Fig. 3-3, p. 68.

Figure 1.1 The observer in the truck sees the ball move in a vertical path when thrown upward. (b) The Earth observer views the path of the ball as a parabola.

Slide 1Fig. 4.1, p.78. Slide 2Fig. 4.3, p.78 Slide 3Fig. 4.4, p.80.

Follow Up Questions Diabetes is caused by an increase in blood glucose. People with diabetes II also have a very high risk for developing Alzheimer’s disease.

Slide 1Fig 28-CO, p.858. Slide 2Fig 28-1, p.859 Slide 3Fig Q28-19, p.884.

Human embryonic stem cells Human induced pluripotent stem cells Yamanaka S. et al. Cell 2007 Thomson J. et al. Science 2007.

Supplementary Figure 1. Suzuki et al. DAPI/BrdU BrdU 24 hrs 48 hrs 72 hrs.

Kami, et al. Supplementary Fig. S2A. Kami, et al. Supplementary Fig. S2B.

Nardella et al. Supplementary Fig. 1 Murine Rheb wt Line 47 Line 50 Log gene expression (a.u.) ******* 200 bp Founders

Supplementary table 1 Clinical data of the female patients with and without diabetes (n) DiabetesNon-diabetes p value 58.6 ± 8.5 (3)54.3 ± 4.1 (3) 5.49.

Fig. 2 from Fabrication of multilayer Pb(Zr,Ti)O3 thin film by sputtering deposition for MEMS actuator applications (Image 1 of 3) Ryo Sano et al 2015.

T+3 WL kDa pI Supplementary Fig. 1.　Confirmation of the.

Fig. 5. The measurement of phosphorylation of p53 level in N2A cells under high glucose condition and agmatine treatment. (A, B) p53 phosphorylation levels.

Fig. 2. Infection by lentivirus

Hire Toyota Innova in Delhi for Outstation Tour

Supplementary Figure 1. Peroxidability index and ARA:EPA index.

Sequence alignment of C-terminal phosphorylated plant aquaporins

Phosphorylation and sequence disorder in microtubule-associated protein Tau.A, schematic illustration of the domain profile of Tau with all known phosphorylation.

Rank-order bar chart of percentage of patient-days with blood glucose results > 299 mg/dl for non-ICU units. Rank-order bar chart of percentage of patient-days.

by Douglas D. Ross, Judith E. Karp, Tar T. Chen, and L. Austin Doyle

Peixoto et al, Supplementary Figure 4.1 A(top)

Kan et al. Suppl. Fig. S1 A B Yellowstone Lake Inflated Plain Otter

Altered interferon signaling with JAK1 loss-of-function mutation in M431 and interferon gamma-inducible PD-L1 expression by 48 melanoma cell lines. Altered.

Flowchart of literature search for the effect of fructose on glycemic end points (fasting glucose, fasting insulin, and glycated blood proteins [HbA1c.

The means and SDs of the data from all Glucommander runs from 1984 to 1998 are graphed. The means and SDs of the data from all Glucommander runs from 1984.

a c b d e * * －＋ Supplementary Figure 0.2 HCF (ALP / G3PDH) 0.1 SK-1

Volatile compounds detected in cheese by GC-MS and faceted heat map showing the variation of volatile compounds between the cheeses at days 0, 18, 24,

Results from the Morris water task.

Distribution of the phosphoproteins based on GO analysis, including biological process (Left) and cellular component (Right). Distribution of the phosphoproteins.

Fig. 5. Nutlin-3 treatment rescues the proliferation and differentiation of NPCs in vitro. Nutlin-3 treatment rescues the proliferation and differentiation.

Involvement of PI3K activation in TCR/CD3-dependent HIF-1α protein expression. Involvement of PI3K activation in TCR/CD3-dependent HIF-1α protein expression.

Supplementary Fig S1, Zembutsu H et al.

Fig. 5. Prip silencing enhances the co-localization of GABARAP with insulin vesicles and β-tubulin.Co-localization of GABARAP (green) with insulin (red)

Fig. 2. Histone H3 phosphorylation appears at prometaphase upon C4 treatment.(A) Western blots were realized on cells synchronized at mitotic entry in.

Fig. 4. The model of malate metabolism in fruit cells under different K level conditions. The model of malate metabolism in fruit cells under different.

Fig. 2. Ex vivo inducible knockout of PDCD2 in ESCs results in loss of S phase entry and increased p53.(A) Growth curve of inducible knockout and WT ESCs.

Response of BW YPO consomic males to glucose and insulin challenges.

Percentage of patients with type 2 diabetes with A1C < 7% (n = 248), blood pressure > 130/80 mmHg (n = 248), and LDL cholesterol < 100 mg/dl (n = 207)

Cell proliferations, ROS production, and ATP levels in HASMCs cultured under high-glucose condition. Cell proliferations, ROS production, and ATP levels.

IRS-1 and -2 expression in four mesangial cell lines from different D-NOD (A and B) and ND-NOD (C and D) mice. IRS-1 and -2 expression in four mesangial.

Effects of in vivo AICAR treatment on blood glucose and lactate concentrations. Effects of in vivo AICAR treatment on blood glucose and lactate concentrations.

Wrch-1 binds to the regulatory p85 subunit of PI3K and is necessary for Akt activation. Wrch-1 binds to the regulatory p85 subunit of PI3K and is necessary.

The rudimentary human β-cell mitogenic signaling road map.

Fig. 3 Glucose- and structure-dependent insulin release.

NF-κB is central to the relationship between UA and cognitive dysfunction. NF-κB is central to the relationship between UA and cognitive dysfunction. The.

Mast cell and microglial proliferation in the developing POA

T-cell phenotypes of cells harvested from the peripheral blood of patients undergoing chemotherapy. T-cell phenotypes of cells harvested from the peripheral.

Fig. 4 Experimental outputs.

Study overview. Study overview. A, Schematic illustrating clinical trial design and the nature and number of tissue specimens available for downstream.

Immunohistochemistry for phosphorylated (S235) S6 ribosomal protein and quantitation of Ki67 labeling indices in vehicle- and WAY –treated Eker (Tsc2+/−)

Schematic representation of the control of muscle glucose uptake during exercise. Schematic representation of the control of muscle glucose uptake during.

The continuous line represents the sensor glucose values.

HPV–human protein network map.

UA acts as an inflammatory stimulus and activates NF-κB in hippocampus

BCL-2 and BCL-XL expression alters with maturation stage of the T cell

Cell-cycle regulatory proteins were controlled by O-GlcNAc at FOXO3 S284 through MDM2. Cell-cycle regulatory proteins were controlled by O-GlcNAc at FOXO3.

Elevated blood glucose vs time.

Immunoreactivity for the lipocalin 2 (LCN2) receptor (SLC22A17), glial fibrillary acidic protein (GFAP), Iba-1 and neuronal nuclei (NeuN) 24 h after intraventricular.

Phenotypic diversity of less predominant B-lineage clones.

Technology schematic for phenotypic tracking of single molecularly defined B-lineage clones. Technology schematic for phenotypic tracking of single molecularly.

**** *** * **** **** *** Shahriary et al.- Supplementary Figure 4 (a)

Presentation transcript:

a b c d e Moriguchi et al., Supplementary Fig. S1 Latency on retention trials (s) a b c d e Discrimination index (%) Latency on first trials (s) Total arm entries Alternations (%) Moriguchi et al., Supplementary Fig. S1

a b c Moriguchi et al., Supplementary Fig. S2 fEPSP slope (% of cont) fEPSP amplitude (mV) Moriguchi et al., Supplementary Fig. S2

a b Moriguchi et al., Supplementary Fig. S3 Phosphorylation (% of cont) Moriguchi et al., Supplementary Fig. S3

a b Moriguchi et al., Supplementary Fig. S4

a b Moriguchi et al., Supplementary Fig. S5 K+ current (pA) Cont Mem Pin 50 pA Moriguchi et al., Supplementary Fig. S5

a b Moriguchi et al., Supplementary Fig. S6 Kir6.1 NeuN Merged Kir6.2 MAP2 Merged Kir6.2 MAP2 Merged Kir6.1 GFAP Merged Kir6.2 GFAP Merged Moriguchi et al., Supplementary Fig. S6

a b c Moriguchi et al., Supplementary Fig. S7 Protein levels (% of cont) Protein levels (% of cont) Moriguchi et al., Supplementary Fig. S7

a b c d e f g h i Moriguchi et al., Supplementary Fig. S8 Latency on retention trials (s) a b c Discrimination index (%) d Latency on first trials (s) e Total arm entries Alternations (%) f g h i Protein levels (% of cont) fEPSP slope (% of cont) fEPSP slope (% of cont) Moriguchi et al., Supplementary Fig. S8

a b c Moriguchi et al., Supplementary Fig. S9 Phosphorylation (% of cont) Protein levels (% of cont) Moriguchi et al., Supplementary Fig. S9

a b c d e f g Moriguchi et al., Supplementary Fig. S10 Latency on retention trials (s) a b c d e Discrimination index (%) Latency on first trials (s) Total arm entries Alternations (%) f g fEPSP slope (% of cont) fEPSP slope (% of cont) Moriguchi et al., Supplementary Fig. S10

a b c d Moriguchi et al., Supplementary Fig. S11 fEPSP slope (% of cont) fEPSP slope (% of cont) c d Phosphorylation (% of cont) Moriguchi et al., Supplementary Fig. S11

a b Moriguchi et al., Supplementary Fig. S12 Phosphorylation (% of cont) Moriguchi et al., Supplementary Fig. S12

a b c d Moriguchi et al., Supplementary Fig. S13 Immobility time (s) Number of BrdU-positive cells/ area Moriguchi et al., Supplementary Fig. S13

a b c d Moriguchi et al., Supplementary Fig. S14 Immobility time (s) Number of BrdU-positive cells/ area Moriguchi et al., Supplementary Fig. S14

Moriguchi et al., Supplementary Fig. 15 Blood glucose levels (mg/dl) Moriguchi et al., Supplementary Fig. 15